HAWTHORNE, N.Y. — Acorda Therapeutics (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President and CEO, will present at the upcoming 2006 BIO Investor Forum on Wednesday, October 18 at 1:20 p.m. Pacific Daylight Time (PDT).
The conference is taking place at The Palace Hotel, San Francisco, CA. The presentation will be available via a live webcast at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ACOR &item_id=1399881 (Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists.)
This webcast will also be archived for 60 days on Acorda’s website at www.acorda.com.
Most Popular
10 Jobs That Pay $30 An Hour
Cross Cultural Management In The Age Of Globalization
3 Questions No Job Seeker Ever Wants To Be Asked?
Today’s Best Part-Time Jobs
5 Regular Mistakes In Public Speaking
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics’ ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics’ operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics’ filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company’s marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda’s lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company’s pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning